First Genetic Disease Screening Kit For Consumers Gets FDA Approval

By Daniel J. Solomon April 7, 2017

23andMe, the genetic testing service co-founded by Anne Wojcicki, has won landmark approval to administer tests for risk of developing 10 hereditary illnesses. In a new ruling, the Food and Drug Administration reversed its 2013 decision to deny the company approval.

Included among the conditions it screens are Parkinson’s Disease, Alzheimer’s Disease, celiac disease and Gaucher Disease –- a rare ailment suffered mostly by Ashkenazi Jews, which results in bone and joint pain, spleen issues and potential neurological damage.

23andMe offers a package in which consumers provide a DNA sample to the company and for $199 get a report breaking down their ethnic ancestry and risk for a host of diseases.

Vox notes that this makes it “the first company to sell regulator-approved genetic predisposition tests directly to consumers.”

FDA officials, while approving the company’s plans, warned that genetic testing is not the final word on whether a person will develop a given illness. “It is important that people understand that genetic risk is just one piece of the bigger puzzle, it does not mean they will or won’t ultimately develop a disease,” Jeffrey Shuren, head of the agency’s Center for Devices and Radiological Health, wrote in a statement.

Contact Daniel J. Solomon at [email protected] or on Twitter @DanielJSolomon

Daniel J. Solomon is the former Assistant to the Editor/News Writer at the Forward. Originally from Queens, he attended Harvard as an undergraduate, where he wrote his senior thesis on French-Jewish intellectual history. He is excited to have returned to New York after his time in Massachusetts. Daniel’s passions include folk music, cycling, and pointed argument.

A message from our Publisher & CEO Rachel Fishman Feddersen

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.

The coming year promises to be filled with more complex and historic developments. We are entering an era where independent, fact-based Jewish journalism will be more important than ever. We need to be ready for whatever 2025 will bring, and with your help, we can be.

We’ve set a goal to raise $260,000 by December 31. That’s an ambitious goal, but one that will give us the resources we need to invest in the high quality news, opinion, analysis and cultural coverage that isn’t available anywhere else.

If you feel inspired to make an impact, now is the time to give something back. Join us as a member at your most generous level.

— Rachel Fishman Feddersen, Publisher and CEO